SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

Correspondence 0001140361-24-002650 from Ernexa Therapeutics Inc. (ERNA)

Ernexa Therapeutics Inc.
Date: Jan. 18, 2024 · CIK: 0000748592 · Accession: 0001140361-24-002650

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-276493

Date
January 18, 2024
Author
Sandra Gurrola
Form
CORRESP
Company
Ernexa Therapeutics Inc.

Letter

ETERNA THERAPEUTICS INC.

1035 Cambridge Street, Suite 18A

Cambridge, MA 02141

January 18, 2024

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attention: Lauren S. Hamill

Re:

Eterna Therapeutics Inc.

Registration Statement on Form S-3

Filed January 12, 2024

File No. 333-276493 (the “Registration Statement”)

Acceleration Request

Ladies and Gentlemen:

In accordance with Rule 461 of Regulation C promulgated under the Securities Act of 1933, as amended, Eterna Therapeutics Inc. (the “Registrant”) hereby respectfully requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement to Monday, January 22, 2024, at 4:01 p.m., Eastern Time, or as soon as thereafter practicable.

The cooperation of the staff in meeting the timetable described above is very much appreciated.

Please contact Jeffrey P. Schultz of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel to the Registrant, at (212) 692-6732 with any questions regarding this request.

Very truly yours,
ETERNA THERAPEUTICS INC.

Show Raw Text
CORRESP
1
filename1.htm

    ETERNA THERAPEUTICS INC.

    1035 Cambridge Street, Suite 18A

    Cambridge, MA 02141

    January 18, 2024

    VIA EDGAR

    U.S. Securities and Exchange Commission

    Division of Corporation Finance

    100 F Street, N.E.

    Washington, D.C. 20549

    Attention: Lauren S. Hamill

              Re:

              Eterna Therapeutics Inc.

                Registration Statement on Form S-3

                Filed January 12, 2024

                File No. 333-276493 (the “Registration Statement”)

                Acceleration Request

    Ladies and Gentlemen:

    In accordance with Rule 461 of Regulation C promulgated under the Securities Act of 1933, as amended, Eterna Therapeutics Inc. (the “Registrant”) hereby
      respectfully requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement to Monday, January 22, 2024, at 4:01 p.m., Eastern Time, or as soon as thereafter practicable.

    The cooperation of the staff in meeting the timetable described above is very much appreciated.

    Please contact Jeffrey P. Schultz of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel to the Registrant, at (212) 692-6732 with any questions
      regarding this request.

            Very truly yours,

            ETERNA THERAPEUTICS INC.

            /s/ Sandra Gurrola

            Sandra Gurrola

            Senior Vice President of Finance

              cc:

              Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

                Jeffrey P. Schultz, Esq.

                Cheryl Reicin, Esq.